2016 (v.24 no.1)
Translational and Clinical Pharmacology
Korean Society for Clinical Pharmacology and Therapeutics
Clinical pharmacologic aspects of immune checkpoint inhibitors in cancer therapy
TCP | v.24, no.1, pp.07-12, Mar, 2016
During the past two years, three immune checkpoint inhibitors, ipilimumab, nivolumab and pembrolizumab, have been approved and revolutionized cancer immunotherapy. Translational andclinical pharmacology of these agents have contributed in identifying patients who will receivebenefit, dose effect relationship and surrogate endpoints of clinical benefit. In addition, populationpharmacokinetics/pharmacodynamics have facilitated scientific clinical development, which has ledto accelerated approval of these agents. This paradigm may show how early phase studies may allowidentification of subgroup of patients who can benefit and subsequent approval of drugs based onsmaller patient population. This may speed the access of effective treatment for patients with lifethreatening diseases.
immune checkpoint inhibitor, immunotherapy, pharmacokinetics